Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Graft vs Host Disease 1

Interventions

Cyclophosphamide 170Rituximab 143Specimen Handling 82venetoclax 79fludarabine 79obinutuzumab 67Vincristine 67Doxorubicin 65Biopsy 64Prednisone 63Magnetic Resonance Spectroscopy 63zanubrutinib 52Lenalidomide 52Dexamethasone 48Cytarabine 43Methotrexate 42blinatumomab 40Immunotherapy, Adoptive 38acalabrutinib 37Bendamustine Hydrochloride 37Etoposide 32fludarabine phosphate 31ibrutinib 28glofitamab 28polatuzumab vedotin 26pirtobrutinib 24orelabrutinib 24Gemcitabine 23Injections 21pembrolizumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × vedolizumab × Lymphoid × Clear all
NCT06815003 2025-06-27

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

City of Hope Medical Center

Phase 2 Recruiting
35 enrolled
LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡